Table 2.
Oral antidiabetic therapy
| 4–9 months prior | Study visit | |||||||
|---|---|---|---|---|---|---|---|---|
| Proportion (%) | Mean dose (mg) | Proportion (%) | Mean dose (mg) | |||||
| GLAR | NPH | GLAR | NPH | GLAR | NPH | GLAR | NPH | |
| Metformin | 83.6 | 89.4 | 1564 ± 599 | 1531 ± 557 | 87.3 | 92.1 | 1605 ± 547 | 1552 ± 552 |
| Meglitinide | 20.7 | 15.9 | 31.2 | 17.3 | ||||
| Repaglinide | 20.4 | 15.5 | 5.3 ± 2.4 | 4.9 ± 1.9 | 31.2 | 17.3 | 5.3 ± 2.4 | 5.1 ± 2.4 |
| Nateglinide | 0.2* | 0.4* | –* | –* | – | – | – | – |
| α-glucosidase inhibitor | 7.9 | 8.7 | 3.2 | 6.1 | ||||
| Acarbose | 7.9 | 8.7 | 173 ± 81 | 205 ± 82 | 2.9 | 5.8 | 200 ± 92 | 203 ± 78 |
| Miglitol | – | – | – | – | 0.3 | 0.3 | 125 ± 35 | 100 ± 0 |
| Sulfonylurea | 28.2 | 25.0 | 17.6 | 18.5 | ||||
| Gliclazide | 3.7 | 1.5 | 163 ± 90 | 155 ± 74 | 2.8 | 1.2 | 100 ± 89 | 125 ± 47 |
| Glipizide | 0.7 | 0.8 | 15 ± 0 | 10 ± 7 | 0.6 | 0.3 | 12 ± 6 | 10 ± 0 |
| Glibenclamide | 10.1 | 8.0 | 12 ± 4 | 11 ± 5 | 2.5 | 3.3 | 13 ± 4 | 12 ± 4 |
| Glipentide | 0.3 | – | 3 ± 1 | – | 0.3 | – | 4 ± 0 | – |
| Glimepiride | 13.3 | 14.4 | 5 ± 2 | 6 ± 4 | 11.6 | 13.4 | 5 ± 2 | 6 ± 4 |
| Glitazone | 2.7 | 1.5 | 3.8 | 3.6 | ||||
| Pioglitazone | 1.9 | 0.8 | 28 ± 5 | 30 ± 0 | 2.2 | 2.4 | 30 ± 9 | 30 ± 8 |
| Rosiglitazone | 0.8 | 0.8 | 6 ± 2 | 6 ± 3 | 1.5 | 1.2 | 5 ± 3 | 6 ± 2 |
*
One patient in each group was receiving nateglinide, but the dose was not recorded. GLAR, insulin glargine group; NPH, neutral protamine Hagedorn.